[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations]. [electronic resource]
Producer: 20080710Description: 3-7 p. digitalISSN:- 0399-8320
- Antineoplastic Agents -- adverse effects
- Benzenesulfonates -- adverse effects
- Carcinoma, Hepatocellular -- drug therapy
- Clinical Protocols
- Contraindications
- Disease-Free Survival
- Humans
- Liver Neoplasms -- drug therapy
- Neoadjuvant Therapy
- Niacinamide -- analogs & derivatives
- Palliative Care
- Phenylurea Compounds
- Protein Kinase Inhibitors -- adverse effects
- Pyridines -- adverse effects
- Randomized Controlled Trials as Topic
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Remission Induction
- Sorafenib
- Survival Rate
- raf Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Practice Guideline
There are no comments on this title.
Log in to your account to post a comment.